Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

667
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
667
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

466
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
466
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

534
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
534
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

552
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
552
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

419
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
419
Ventilatory Modes01:14

Ventilatory Modes

1.8K
Mechanical ventilators are life-saving devices that support or replace spontaneous breathing. They deliver breaths to patients through varying methods known as ventilator modes. Understanding these modes is critical for healthcare providers managing patients with respiratory failure.
There are three ventilatory modes: full support, partial support, and spontaneous. These are described below.
Full Support Modes
Full support modes include controlled mechanical ventilation, continuous mandatory...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Right Ventricular Metrics as End Points in Clinical Trials: A Review.

JAMA cardiology·2026
Same author

Comprehensive clinical benefit of CCM in HFrEF patients: a win-ratio analysis of FIX-HF-5C randomized trial.

ESC heart failure·2026
Same author

Universal Pulmonary Resistance-Compliance Relationship: And Why It Matters?

Circulation. Heart failure·2026
Same author

De Novo Aortic Insufficiency and Its Progression in Patients on Microaxial Flow Pump Support Before Durable Left Ventricular Assist Device.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Cardiac microcurrent therapy in heart failure: Mechanistic rationale, early clinical evidence, and future directions.

Heart failure reviews·2026
Same author

Does Pacemaker Mode Affect Outcomes in Patients With HeartMate 3 LVAD?

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026

Related Experiment Video

Updated: Feb 26, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.2K

Mechanical Circulatory Support Devices for Acute Right Ventricular Failure.

Navin K Kapur1, Michele L Esposito2, Yousef Bader2

  • 1From The Cardiovascular Center, Tufts Medical Center, Boston, MA (N.K.K., M.L.E., Y.B., K.J.M., M.S.K.); Department of Cardiac Surgery, Northwestern University Medical Center, Chicago, IL (D.T.P.); and Cardiovascular Research Foundation, New York, NY (D.B.). nkapur@tuftsmedicalcenter.org.

Circulation
|July 19, 2017
PubMed
Summary

Right ventricular (RV) failure is a significant cause of death. Acute mechanical circulatory support pumps offer a vital option for stabilizing patients with RV failure and cardiogenic shock.

Keywords:
assisted circulationhemodynamicsventricular dysfunction, right

More Related Videos

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.4K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.0K

Related Experiment Videos

Last Updated: Feb 26, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.2K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.4K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.0K

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Biomedical Engineering

Background:

  • Right ventricular (RV) failure is a critical determinant of morbidity and mortality in advanced heart failure, pulmonary hypertension, and post-cardiac surgery.
  • Percutaneously delivered acute mechanical circulatory support (RV MCS) devices have emerged as a key therapeutic option over the last two decades.
  • RV MCS plays a crucial role in stabilizing patients experiencing cardiogenic shock involving the RV.

Purpose of the Study:

  • To review the pathophysiology of acute RV failure.
  • To discuss the mechanisms of action and clinical utility of current RV MCS devices.
  • To highlight the evolving role of RV MCS in patient management.

Main Methods:

  • Literature review of existing RV acute mechanical circulatory support devices.
  • Analysis of clinical data on the efficacy and application of RV MCS.
  • Discussion of the pathophysiology of acute RV failure.

Main Results:

  • RV acute mechanical circulatory support is an established intervention for RV failure.
  • The effectiveness of RV MCS is increasingly reliant on optimized patient selection, monitoring, and weaning protocols.
  • Existing RV MCS devices offer rapid stabilization for RV cardiogenic shock.

Conclusions:

  • RV MCS is an integral part of managing RV failure.
  • Future advancements in RV MCS will focus on improved patient management strategies beyond technical implantation.
  • Optimizing algorithms for RV failure identification, patient monitoring, and weaning protocols is essential for maximizing the benefit of RV MCS.